U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C76H104N18O19S2
Molecular Weight 1637.878
Optical Activity UNSPECIFIED
Defined Stereocenters 15 / 15
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SOMATOSTATIN

SMILES

[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@]([H])(NC(=O)[C@H](CC6=CC=CC=C6)NC1=O)[C@@H](C)O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O

InChI

InChIKey=NHXLMOGPVYXJNR-ATOGVRKGSA-N
InChI=1S/C76H104N18O19S2/c1-41(79)64(100)82-37-61(99)83-58-39-114-115-40-59(76(112)113)92-72(108)57(38-95)91-75(111)63(43(3)97)94-71(107)54(33-46-23-11-6-12-24-46)90-74(110)62(42(2)96)93-66(102)51(28-16-18-30-78)84-69(105)55(34-47-36-81-49-26-14-13-25-48(47)49)88-68(104)53(32-45-21-9-5-10-22-45)86-67(103)52(31-44-19-7-4-8-20-44)87-70(106)56(35-60(80)98)89-65(101)50(85-73(58)109)27-15-17-29-77/h4-14,19-26,36,41-43,50-59,62-63,81,95-97H,15-18,27-35,37-40,77-79H2,1-3H3,(H2,80,98)(H,82,100)(H,83,99)(H,84,105)(H,85,109)(H,86,103)(H,87,106)(H,88,104)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t41-,42+,43+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,62-,63-/m0/s1

HIDE SMILES / InChI

Molecular Formula C76H104N18O19S2
Molecular Weight 1637.878
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 15 / 15
E/Z Centers 2
Optical Activity UNSPECIFIED

Somatostatin (also known as growth hormone-inhibiting hormone) is a naturally-occurring peptide hormone that regulates the endocrine system. Somatostatin is produced in gastrointestinal (GI) tract, pancreas, hypothalamus, and central nervous system (CNS) and some other organs. Somatostatin is initially secreted as a 116 amino acid precursor, preprosomatostatin, which undergoes endoproteolytic cleavage to prosomastatin. Prosomastatin is further process into two active forms, shorter isoform somatostatin-14 works primarily in the brain, while the longer somatostatin-28 (SST-28) form operates in the GI tract. Somatostatin produces predominantly neuroendocrine inhibitory effects across multiple systems. It is known to inhibit GI, endocrine, exocrine, pancreatic, and pituitary secretions, as well as modify neurotransmission and memory formation in the CNS. Somatostatin binds to six different receptors in various systems and cells throughout the body to produce its regulatory effect. These receptors are specific to somatostatin and classify as G-protein coupled receptors (GPCR). Somatostatin half-life is between 1 to 3 minutes. Due to its short half-life, somatostatin has been formulated exogenously in much more stable forms with a longer half-life; this allows for its primary clinical use, which is the treatment of neuroendocrine tumors.

Approval Year

PubMed

PubMed

TitleDatePubMed
Effects of mexiletine on algogenic mediator-induced nociceptive responses in mice.
1999 Jul-Aug
Design, synthesis, and evaluation of novel 3,6-diaryl-4-aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2.
2011 Apr 14
Patents
Substance Class Chemical
Created
by admin
on Sat Dec 16 19:47:46 GMT 2023
Edited
by admin
on Sat Dec 16 19:47:46 GMT 2023
Record UNII
6E20216Q0L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SOMATOSTATIN
EP   INN   MART.   MI   WHO-DD  
INN  
Official Name English
SOMATOSTATIN [MART.]
Common Name English
SRIF-14
Code English
SOMATOSTATIN-14
Common Name English
Somatostatin [WHO-DD]
Common Name English
SOMATOSTATIN [MI]
Common Name English
somatostatin [INN]
Common Name English
SOMATOSTATIN [EP MONOGRAPH]
Common Name English
ALA-GLY-CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS 3,14-disulfide
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 21587
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
FDA ORPHAN DRUG 86094
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
LOINC 2960-3
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
LOINC 49792-5
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
WHO-VATC QH01CB01
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
WHO-ATC H01CB01
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
LOINC 2961-1
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
Code System Code Type Description
FDA UNII
6E20216Q0L
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
CAS
51110-01-1
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
NO STRUCTURE GIVEN
SMS_ID
100000092022
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
DRUG BANK
DB09099
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
DRUG CENTRAL
2997
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
ChEMBL
CHEMBL1823872
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
CAS
38916-34-6
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
EVMPD
SUB12320MIG
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
MERCK INDEX
m10111
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY Merck Index
PUBCHEM
16129706
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
INN
4311
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
CHEBI
64628
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
ECHA (EC/EINECS)
254-186-5
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
EPA CompTox
DTXSID8046793
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
RXCUI
9939
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
256-969-7
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
ALTERNATIVE
MESH
D013004
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
NCI_THESAURUS
C836
Created by admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
PRIMARY
Related Record Type Details
DERIVATIVE -> PARENT
DERIVATIVE -> PARENT
AGONIST -> TARGET
INDUCER -> TARGET
ACTIVATES RELEASE OF SOMATOSTAIN
INGREDIENT -> STARTING MATERIAL
DERIVATIVE -> PARENT
DERIVATIVE -> PARENT
DERIVATIVE -> PARENT
DERIVATIVE -> PARENT
DERIVATIVE -> PARENT
DERIVATIVE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY